Benitec Biopharma

Benitec Biopharma Limited
Company type	Public
Traded as	Nasdaq: BNTC
Industry	RNA interference
Founded	1997; 27 years ago
Headquarters	Melbourne, Victoria, Australia
Key people	Michael Graham (founding scientist & head of discovery)
Products	Gene silencing; Gene expression; RNA interference (ddRNAi);
Website	www.benitec.com

Benitec Biopharma Limited is an Australian biotechnology company founded in 1997.^[1] It is engaged in the development of gene-silencing therapies for the treatment of chronic and life-threatening diseases using DNA-directed RNA interference (ddRNAi) technology.^[2]

The CSIRO has researched RNAi extensively, developing the small hairpin RNA concept employed in ddRNAi. Benitec Biopharma has an exclusive license to this ddRNAi technology in human therapeutic uses and research.^[3]

Research and development[edit]

Benitec Biopharma is researching ddRNAi in the following fields:

Hepatitis B (under development with partner Biomics Biotechnologies)^[4])
Oculopharyngeal muscular dystrophy (OPMD)^[5]^[6]

References[edit]

^ "Benitec Biopharma". Australian Securities Exchange. Retrieved 11 April 2012.
^ "GlobalData Financial and Strategic SWOT Analysis Review". GlobalData. Archived from the original on 24 January 2013. Retrieved 11 April 2012.
^ "Licensing RNAi gene technology. CSIRO. 14 Oct 2011". CSIRO. Archived from the original on 18 May 2012. Retrieved 12 April 2012.
^ "Biomics Biotechnologies – Pipeline". Biomics Biotechnologies. Archived from the original on 14 December 2015. Retrieved 21 January 2014.
^ "Bioshares Edition 434. 25 November 2011" (PDF). Bioshares. Archived from the original (PDF) on 20 July 2013. Retrieved 21 January 2014.
^ "Benitec Biopharma Annual Report 2011" (PDF). Benitec. Archived from the original (PDF) on 19 July 2013. Retrieved 16 January 2014.

External links[edit]

Benitec Biopharma website

[Australian_Securities_Exchange_–_Benitec_Biopharma_Limited-1] "Benitec Biopharma". Australian Securities Exchange. Retrieved 11 April 2012.

[GlobalData_Financial_and_Strategic_SWOT_Analysis_Review_–_Benitec_Biopharma._Apr_2012-2] "GlobalData Financial and Strategic SWOT Analysis Review". GlobalData. Archived from the original on 24 January 2013. Retrieved 11 April 2012.

[Licensing_RNAi_gene_technology._CSIRO._14_Oct_2011-3] "Licensing RNAi gene technology. CSIRO. 14 Oct 2011". CSIRO. Archived from the original on 18 May 2012. Retrieved 12 April 2012.

[Biomics_Biotechnologies_-_Pipeline-4] "Biomics Biotechnologies – Pipeline". Biomics Biotechnologies. Archived from the original on 14 December 2015. Retrieved 21 January 2014.

[Bioshares_Edition_434._25_November_2011-5] "Bioshares Edition 434. 25 November 2011" (PDF). Bioshares. Archived from the original (PDF) on 20 July 2013. Retrieved 21 January 2014.

[Benitec_Biopharma_Annual_Report_2011-6] "Benitec Biopharma Annual Report 2011" (PDF). Benitec. Archived from the original (PDF) on 19 July 2013. Retrieved 16 January 2014.

[1]

[2]

[3]

[4]

[5]

[6]